Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033384 | 0.75 | SLC40A1 (0.45) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4035865 | 0.75 | MTNR1A (0.40) | MEN1KMT2A | |
| SCHEMBL4033368 | 0.74 | CDK5 (0.45) | PDGFRAKDRFYN | |
| SCHEMBL4034066 | 0.73 | CCNT1 (0.38) | METDDR2PARP2ATMFYN | |
| SCHEMBL13812012 | 0.70 | PTPN1 (0.36) | PDGFRA | |
| SCHEMBL4033403 | 0.66 | MEN1 (0.44) | ATMSRCMEN1KMT2A | |
| SCHEMBL19126747 | 0.62 | GFER (0.54) | ATMMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL19957225 | 0.62 | MET (0.49) | METATMPDGFRAKDRSRC | |
| SCHEMBL23584982 | 0.61 | MET (0.65) | METDDR2PDGFRAKDRSRC | |
| SCHEMBL17144058 | 0.60 | AAK1 (0.59) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307454-B1 | DERIVATIVES OF VARIOLIN B | PHARMA MAR SA (ES) | 2009-06-03 | — | — | EP | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033001-A1 | Derivatives of Variolin B | ARG2, SDHB, OAT | MET 1891/4885DDR2 571/4885PARP2 237/4885 |
| US-20040058939-A1 | Derivatives of variolin b | HNRNPA2B1, HNRNPAB, SYNCRIP | MET 1976/4885DDR2 573/4885PARP2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.